OTC · Biotechnology

Lyra Therapeutics, Inc. (LYRA) Stock

$0.52 +0.00% OTC: LYRA Healthcare

Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS).

Valuation

MetricValue
Price$0.52
Market Cap$922939
P/E Ratio-0.03
P/B Ratio-0.75
P/S Ratio2.32
EPS (TTM)$-18.62
52-Week High$8.75
52-Week Low$0.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE263.64%
ROA-80.09%
ROCE-116.69%
Gross Margin100.00%
Operating Margin-98728.57%
Net Margin0.00%
Debt/Equity-2.82
Current Ratio1.71

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$1.0M$2.0M$2.0M$0
Operating Profit$-44.0M$-56.0M$-67.0M$-96.0M$-31.0M
Net Profit$-44.0M$-55.0M$-63.0M$-93.0M$-29.0M
EPS$-3.35$-1.83$-1.26$-1.43$-18.62
Op Margin-15303.5%-4131.0%-4308.1%-6280.8%-7794.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$55.0M$110.0M$143.0M$66.0M$36.0M
Total Liabilities$21.0M$29.0M$53.0M$55.0M$47.0M
Cash$46.0M$33.0M$22.0M$41.0M$16.0M
Borrowings$1.0M$4.0M$27.0M$34.0M$30.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-26.0M$-43.0M$-63.0M$-70.0M$-29.0M
Investing Cash Flow$-7.0M$-65.0M$-14.0M$78.0M$0
Financing Cash Flow$0$-4.0M$-4.0M$0$-1.0M
Net Cash Flow$-29.0M$-12.0M$-10.0M$19.0M$-25.0M
Free Cash Flow$-29.0M$-44.0M$-64.0M$-72.0M$-29.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.55
FCF Yield-3139.43%
Quick Ratio1.71
Interest Coverage0.00
Return 1Y-93.62%
Return 3Y-99.69%
Return 5Y—

Ownership

Insiders Held0.62%
Institutions Held12.53%
Institutions Float Held12.61%
Institutional HolderSharesReport Date
Sabby Management, LLC104,0592026-03-31
Global Retirement Partners, LLC152025-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.

Lyra Therapeutics, Inc. is headquartered in US.

Lyra Therapeutics, Inc. (LYRA) stock trades at $0.52 with a market capitalization of $922939. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of -0.75, price-to-sales of 2.32. Over the past 52 weeks the stock has ranged between $0.30 and $8.75, and currently trades 94.1% below its 52-week high.

On profitability, Lyra Therapeutics, Inc. generates a return on equity (ROE) of 263.64% — well above the market average, a sign of a high-quality business, return on capital employed of -116.69%, an operating margin of -98728.57%, a net profit margin of 0.00%.

Official website: lyratherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides